文献速递药物不良反应与药物警戒特殊人群用药

β受体阻滞剂相关低血糖:真实世界药物警戒研究新见解

Beta-blocker-associated hypoglycaemia: New insights from a real-world pharmacovigilance study.
PubMed 文献 · Br J Clin Pharmacol · 2021-02-23

基于FDA不良事件报告系统数据库的病例/非病例分析显示,纳多洛尔与低血糖关联最强(报告比值比6.98),儿童最易感,长半衰期和非选择性β受体阻滞剂可能增加风险。系统综述纳入7篇研究,低血糖发生率异质性大。

要点

  • 纳多洛尔与低血糖关联最强,报告比值比6.98(95%CI 5.40-9.03)。
  • 儿童病例中长半衰期药物与低血糖正相关(OR 2.232),β1选择性负相关(OR 0.644)。
  • 长半衰期和非选择性β受体阻滞剂可能增加低血糖风险。

核心结论

  • 纳多洛尔是与低血糖关联最显著的β受体阻滞剂,儿童为最易感人群。
  • 长半衰期和非选择性β受体阻滞剂似乎增加低血糖发生风险。

研究设计与样本

  • 对相关临床研究进行系统综述,最终纳入7篇论文。

主要发现

  • 低血糖关联显著:纳多洛尔报告比值比6.98(95%CI 5.40-9.03),塞利洛尔2.35(1.35-4.10),普萘洛尔2.14(1.87-2.46),比索洛尔1.42(1.25-1.61)。
  • 儿童病例(n=310)中,长半衰期药物与低血糖正相关(OR 2.232,95%CI 1.398-3.563),β1选择性负相关(OR 0.644,95%CI 0.414-0.999)。
  • 系统综述中低血糖发生率:普萘洛尔治疗1.73%(总参与者575),阿替洛尔6.6%(n=30),卡维地洛10%(n=20)。

关键数值与推荐

  • 纳多洛尔报告比值比6.98(95%CI 5.40-9.03)与低血糖关联最强。
  • 儿童中长半衰期药物OR 2.232(95%CI 1.398-3.563),β1选择性OR 0.644(95%CI 0.414-0.999)。
  • 系统综述低血糖发生率:普萘洛尔1.73%(575例),阿替洛尔6.6%(30例),卡维地洛10%(20例)。

临床怎么用

  • 使用纳多洛尔、普萘洛尔等非选择性β受体阻滞剂时,应警惕低血糖风险。
  • 儿童患者使用长半衰期β受体阻滞剂时需加强血糖监测。
  • β1选择性β受体阻滞剂在儿童中可能与较低低血糖风险相关。

局限性

  • 系统综述纳入研究在设计 and 人群特征上异质性大,低血糖发生率差异显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the statistical association between hypoglycaemia and β-blocker use and to define what patient and drug characteristics could potentially increase the risk for its occurrence. METHODS: We investigated the relationship between pharmacological parameters of β-blockers and the occurrence of hypoglycaemia by conducting a case/non case analysis using the Food and Drug Administration Adverse Event Reporting System database. Pharmacological properties that could represent a predictive factor for hypoglycaemia were analysed through a multilinear binary logistic regression (null hypothesis rejected for values of P < .05). We also performed a systematic review of clinical studies on this association. RESULTS: Of 83 954 selected reports, 1465 cases (1.75%) of hypoglycaemia were identified. The association was found statistically significant for nadolol (reporting odds ratio [95% confidence interval]: 6.98 [5.40-9.03]), celiprolol (2.35 [1.35-4.10]), propranolol (2.14 [1.87-2.46]) and bisoprolol (1.42 [1.25-1.61]). Paediatric cases (n = 310) showed a positive association with hypoglycaemia for long half-life drugs (odds ratio [95% confidence interval]: 2.232 [1.398-3.563]) and a negative association for β1-selectivity (0.644 [0.414-0.999]). Seven papers were included in the systematic review. Because of great heterogeneity in study design and demographics, hypoglycaemia incidence rates varied greatly among studies, occurring in 1.73% of the cases for propranolol treatment (n total participants = 575), 6.6% for atenolol (n = 30) and 10% for carvedilol (n = 20). CONCLUSION: Nadolol appears to be the β-blocker significantly most associated with hypoglycaemia and children represent the most susceptible sample. Furthermore, long half-life and nonselective β-blockers seem to increase the risk for its occurrence.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Carnovale C, Gringeri M, Battini V, et al. Beta-blocker-associated hypoglycaemia: New insights from a real-world pharmacovigilance study. Br J Clin Pharmacol. 2021. PMID: 33506522. doi:10.1111/bcp.14754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。